Anti-HMdU Autoantibodies in Human Sera as a Biomarker of Cancer Risk
Our laboratory has discovered that blood sera of healthy men and women contain low levels of anti-HMdU (Shydroxymethyl-2′-deoxyuridine, an oxidized thymidine) autoantibodies (aAbs) (1 ,2 ) However, patients with chronic inflammatory diseases exhibit elevated anti-HMdU aAb titers. Interestingly, people at high risk for cancer, those with cancer and, most importantly, those who were diagnosed with breast, colon, and rectal cancer 0.5–6 yr after donation of the blood samples we analyzed (but not those diagnosed with nonmelanoma skin cancer) had significantly elevated anti-HMdU aAb titers (4 ). The high aAbs in apparently healthy women at the time of blood donation persisted for several years before diagnosis (3 ). We recently also showed that these anti-HMdU aAb titers depend on subject’s age and menopausal status (5 ) Our findings pomt to anti-HMdU aAb titers as being a biomarker of a potential to develop cancer even in the absence of family risk factors, which constitute the majority of cases
- Detection of Apoptosis in Renal Cell Carcinoma
- Modulation of Apoptosis to Reverse Chemoresistance
- Syngeneic Murine Metastasis Models: B16 Melanoma
- Factors Affecting Immunohistochemical Evaluation of Biomarker Expression in Neoplasia
- Clinical Implications of Epigenetic Alterations in Human Thoracic Malignancies: Epigenetic Alterations in Lung Cancer
- Recent Advances and Dilemmas in the Radiotherapeutic Management of Locally Advanced Non-Small Cell Lung Cancer
- Cancer Gene Profiling in Prostate Cancer
- Detection of the FIP1L1-PDGFRA Fusion in Idiopathic Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia
- Principles of Cancer Cell Culture
- Overview of Novel Anticancer Drug Targets